Quantcast

Latest 5-HT3 antagonist Stories

2008-11-03 09:00:40

A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceuticals company, today announced that Ronald J. Prentki, the Company's president and chief executive officer, will present at the Rodman & Renshaw 10th Annual Healthcare Conference, on Wednesday, November 12, 2008, at 10:20 a.m. Eastern time at The Palace Hotel in New York City. Interested parties can access a live audio webcast at www.appharma.com. An archived presentation will be available on the Company's Web site for 14 days....

2008-09-30 06:00:14

A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, announced today positive results from its pivotal Phase 3 study comparing the efficacy of APF530 (the Company's proprietary, sustained release formulation of granisetron) with Aloxi(R) for the prevention of chemotherapy induced nausea and vomiting (CINV). Patients in the study were classified into moderately or highly emetogenic chemotherapy levels according to the Hesketh algorithm, which assigns emetogenic levels based on...

2008-09-17 00:00:07

By The Associated Press WASHINGTON (AP) - Cancer patients will soon be able to use a medication patch to ease the debilitating nausea that often accompanies chemotherapy.The Food and Drug Administration said Monday it has approved the first anti-nausea patch for chemotherapy patients, intended to provide relief for up to five days. The patch, called Sancuso, is worn on the arm and delivers a widely used anti- nausea medicine, known as granisetron, through the skin. It is expected to be...

2008-09-16 09:00:53

ProStrakan Group has received the FDA approval for Sancuso, which is reported to be the first and only patch to provide up to five consecutive days of control of nausea and vomiting for patients receiving a moderately or highly nausea-inducing chemotherapy regimen. According to the company, Sancuso is a transdermal system, or skin patch, that delivers granisetron, its active component and an established inhibitor of nausea and vomiting, through a thin layer of adhesive that attaches the...

2008-09-16 09:00:06

By Associated Press WASHINGTON -- Cancer patients will soon be able to use a medication patch to ease the debilitating nausea that often accompanies chemotherapy. The Food and Drug Administration said Monday it has approved the first anti-nausea patch for chemotherapy patients, intended to provide relief for up to five days. The patch, called Sancuso, is worn on the arm and delivers a widely used anti-nausea medicine, known as granisetron, through the skin. It is expected to be available...

2008-09-15 09:00:11

BEDMINSTER, N.J., Sept. 15 /PRNewswire-FirstCall/ -- ProStrakan Group plc today announced the U.S. Food and Drug Administration (F.D.A) approval of SANCUSO(R) (Granisetron Transdermal System), the first and only patch to provide up to five consecutive days of control of nausea and vomiting for patients receiving a moderately and/or highly nausea-inducing chemotherapy regimen. Chemotherapy-induced nausea and vomiting (CINV) are commonly cited by patients undergoing chemotherapy as highly...

2008-08-23 12:00:22

WOODCLIFF LAKE, N.J., Aug. 23 /PRNewswire/ -- Eisai Corporation of North America and its partner Helsinn Healthcare SA today announced that the U.S. Food and Drug Administration (FDA) has approved a new oral formulation of ALOXI(R) (palonosetron hydrochloride) for the prevention of chemotherapy-induced nausea and vomiting (CINV). ALOXI Capsules 0.5 mg for oral administration is indicated for the prevention of acute nausea and vomiting following initial and repeat courses of moderately...

2008-08-14 06:00:46

A.P. Pharma, Inc. (NASDAQ: APPA), a specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2008. Highlights Operational: -- Ronald Prentki appointed President, Chief Executive Officer and Director -- APF530 (prevention of chemotherapy-induced nausea and vomiting) -- Patient enrollment completed in Phase 3 trial -- Announcement of trial results remains targeted for late Q3 2008 -- NDA submission planned for late 2008 -- Product pipeline...

2008-07-21 12:00:20

Astellas Pharma has received a Japanese marketing approval for Irribow tablets 2.5 microgram and 5 micro gram for the diarrhea-predominant irritable bowel syndrome in male. Irribow is a serotonin 5-HT3 receptor antagonist discovered by Astellas. According to the company, Irribow improves abnormal defaecation associated with the acceleration of intestinal transit by inhibiting 5-HT3 receptor selectively. It is also said to improve visceral hypersensitivity by suppressing the transmission of...

2008-07-10 09:01:29

Helsinn Healthcare and Eisai have announced the availability in the US of Aloxi injection 0.075mg for the prevention of postoperative nausea and vomiting for up to 24 hours following surgery. Approved by the FDA for postoperative nausea and vomiting, Aloxi injection 0.075mg is administered as a single IV dose immediately before induction of anesthesia to prevent PONV for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. Aloxi has been available in the...


Word of the Day
siliqua
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'
Related